How is panitumumab used in the treatment of wild-type RAS (both KRAS and NRAS) metastatic colorectal cancer?

Updated: Apr 15, 2020
  • Author: Tomislav Dragovich, MD, PhD; Chief Editor: N Joseph Espat, MD, MS, FACS  more...
  • Print

In June 2017, the FDA extended approval for panitumumab for use in wild-type RAS (both KRAS and NRAS) metastatic colorectal cancer. Approval was based on a retrospective analysis from the PRIME trial and prospective, pre-defined analyses from the phase 3 '0007 study. The '0007 study evaluated the efficacy of panitumumab plus best supportive care (BSC) versus BSC alone in patients with chemorefractory, wild-type KRAS metastatic colorectal cancer. [119] Key secondary endpoint data showed significant improvement in overall survival (OS) of 10 months in BSC with panitumumab compared to 6.9 months with BSC alone.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!